Lv5
1380 积分 2024-08-09 加入
Comparative study of Rb1, cyclin D1 and p16 immunohistochemistry expression to distinguish lung small‐cell carcinoma and large‐cell neuroendocrine carcinoma
6天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
8天前
已完结
PT2.13.02 Multi-Cycle Low-Dose Radiotherapy Reshapes Immunochemotherapy for ES-SCLC: The SPUR Phase II Trial
8天前
已关闭
PT2.13.01 A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC
8天前
已关闭
Two patients suffering from NSCLC with a novel rearrangement mutation in RET (exon2-11del) and their response to pralsetinib as salvage treatment
10天前
已关闭
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)
10天前
已完结
Abstract CT201: HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients
11天前
已关闭
First-line versus second-line use of selpercatinib in treatment of RET fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis
11天前
已完结
Selpercatinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway
11天前
已完结
Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion–positive non-small cell lung cancer in the United States
11天前
已完结
皖公网安备34019202002308
